• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Friedreich’s ataxia Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Friedreich’s ataxia.
  • The report assesses Friedreich’s ataxia pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Friedreich’s ataxia pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Friedreich’s ataxia ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

MIGENIX, Edison Pharmaceuticals, Warren Pharmaceuticals, Biovista, STATegics, Catabasis Pharmaceuticals, RaNA Therapeutics, Agilis Biotherapeutics, Repligen Corporation, Voyager Therapeutics, Bioblast Pharma, Retrotope, Cardero Therapeutics, Jupiter Orphan Therapeutics

Key Drugs:

Indolepropionic acid, Alfatradiol, LU AA 24493, A 0001, RG 2833, AGIL FA, Omaveloxolone, RT 001, Epicatechin, Trans-resveratrol oral, Epicatechin, Trans-resveratrol oral, Epicatechin, Trans-resveratrol oral, Epicatechin, Trans-resveratrol oral

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel